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Nuclear targeting of dystroglycan
promotes the expression of androgen
regulated transcription factors in prostate
cancer
G. Mathew1*, A. Mitchell1{, J. M. Down21, L. A. Jacobs1, F. C. Hamdy2#, C. Eaton2, D. J. Rosario3,
S. S. Cross4 & S. J. Winder1
1Department of Biomedical Science, University of Sheffield, Firth Court, Western Bank, Sheffield, S10 2TN, UK, 2Academic Unit of
Urology, 3Department of Oncology, 4Academic Unit of Pathology, Department of Neuroscience, Faculty of Medicine, Dentistry &
Health University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK.
Dystroglycan is frequently lost in adenocarcinoma, but the mechanisms and consequences are poorly
understood. We report an analysis of b-dystroglycan in prostate cancer in human tissue samples and in
LNCaP cells in vitro. There is progressive loss of b-dystroglycan immunoreactivity from basal and lateral
surfaces of prostate epithelia which correlates significantly with increasing Gleason grade. In about half of
matched bone metastases there is significant dystroglycan re-expression. In tumour tissue and in LNCaP
cells there is also a tyrosine phosphorylation-dependent translocation of b-dystroglycan to the nucleus.
Analysis of gene expression data by microarray, reveals that nuclear targeting of b-dystroglycan in LNCaP
cells alters the transcription of relatively few genes, the most unregulated being the transcription factor
ETV1. These data suggest that proteolysis, tyrosine phosphorylation and translocation of dystroglycan to
the nucleus resulting in altered gene transcription could be important mechanisms in the progression of
prostate cancer.
D
ystroglycan is a ubiquitously expressed cell adhesion molecule with crucial roles in the assembly of the
basement membrane1,2, in muscle integrity as a part of the dystrophin glycoprotein complex3,4, and in
basolateral cell adhesion in many epithelial tissues5,6. Loss of these functional roles for dystroglycan give
rise to distinct disease phenotypes including muscular dystrophies and severe neurological phenotypes7.
Additionally, and probably as a consequence of the role of dystroglycan in branching epithelial morphogenesis5,
loss of dystroglycan function is also associated with adenocarcinoma8. Mutations in dystroglycan are not known
to be associated with cancer, indeed to date only one mutation in dystroglycan itself has been described, a single
amino acid substitution, that gives rise to a limb girdle muscular dystrophy phenotype9. Moreover, dystroglycan
transcription appears largely unaltered in the majority of carcinomas. The expression of glycosyltransferase such
as LARGE and b3GnT1 however, which are crucially required for the post-translational modification of dystro-
glycan that gives it its laminin binding function, are downregulated in adenocarcinoma10–12. Furthermore many
studies have reported the absence of dystroglycan protein, or the presence of aberrant short forms of dystroglycan
in cancer (reviewed in13). Coupled with the post-translational alterations to dystroglycan; both hypo-glycosyla-
tion of a-dystroglycan and phosphorylation and proteolysis of b-dystroglycan13, are themore recent findings that
b-dystroglycan is present in the nucleus of both normal and tumour cell lines14–16. We have therefore investigated
b-dystroglycan in clinical samples from prostate tumours, the extent of b-dystroglycan loss, pattern of proteo-
lysis, phosphorylation on tyrosine and subcellular distribution. Furthermore we have investigated the transcrip-
tional response in LNCaP cells to the nuclear targeting of a b-dystroglycan construct.
Results
Dystroglycan immunohistochemistry.We have investigated the expression and localisation of b-dystroglycan
in tissue micro arrays (TMAs) comprising 41 cases of benign prostatic hyperplasia (BPH), 9 cases of prostatic
intraepithelial neoplasia (PIN) and 113 prostate cancers. Immunohistochemistry for b-dystroglycan subunit as
this tends to be less susceptible to tissue to tissue variation and the antibody is insensitive to common
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post-translational changes often observed in a-dystroglycan such as
proteolysis or hypo-glycosylation17. In the epithelium in BPHand the
morphologically normal background of cancer cases therewas strong
dystroglycan expression at the junction between the epithelial cells
and the basement membrane and the intercellular junctions of
epithelial cells and was indistinguishable from the staining pattern
in normal tissue (Figure 1A–D). In tumour samples the intercellular
expression was lost in 41% of cancers and was only weak in a further
37%. The basal expression was lost in 19% of cancers and was only
weak in a further 47%. In the 9 cases of PIN there was strong staining
in both sites in 3 cases, weak staining in 4 cases and intercellular
absence in 2 cases. Increasing Gleason tumour grade was signi-
ficantly associated with the reduction in intercellular expression of
b-dystroglycan (Jonckheere-Terpstra test, p 5 0.027) but not with
the basal expression (p5 0.233) (Supplementary Table 1, Figure 1E–
H). We also examined bone metastases samples and compared the
level of dystroglycan expression in the metastasis with the level of
dystroglycan in a tumour sample from the primary tissue taken from
the same patients. Whilst the overall picture for dystroglycan status
in the larger sample of primary tumour specimens was of a profound
loss of dystroglycan immunoreactivity, the consensus from the
metastasis samples was more varied. Of the 10 pairs of samples, 6
had near normal dystroglycan levels in the primary site and either
showed no change in dystroglycan level between primary and
metastatic site (n 5 3), or showed a slight reduction from the
primary to the metastatic site (n 5 3). However, of the 4 samples
that had reduced or absent dystroglycan in the primary tumour, the
most common situation in the larger patient sample of primary only
data, there was a significant upregulation of dystroglycan in the
secondary metastatic site (Supplementary Table 1, Figure 1IJ).
These data from patient samples follow the general scheme for
dystroglycan loss and re-expression proposed for LNCaP cells
undergoing EMT and MET in vitro13. One of the factors important
in the proteolytic degradation and loss of dystroglycan from the cell
membrane is tyrosine phosphorylation13,18. We made an analysis of
60 prostate TMA specimens using the antibody 1709 which is
specific for b-dystroglycan phosphorylated on tyrosine residue
89018,19. In agreement with previous analyses of cell lines in tissue
culture, a significant number of nuclei were positive for tyrosine
phosphorylated b-dystroglycan (pY b-DG) (Figure 2A–E). Most
often the pY b-DG immunostaining was associated with the basal
cell layer where this is recognisable as such (arrows in Fig. 2). An
elongated nuclear morphology similar to neuroendocrine cells of the
prostate is observed in the darker staining basal cell type. In other
cases however, the staining was present in luminal cells and stromal
cells. Although described previously in cells maintained in vitro, this
is the first report of phosphorylated dystroglycan in cellular nuclei in
any intact tissue.
Biochemical fractionation of dystroglycan. To further investigate
the mechanisms and consequences of nuclear translocation of
phosphorylated dystroglycan we carried out biochemical fractiona-
tion of prostate tissue samples from transurethral resection of the
prostate (TURP). Western blots of extracts from both normal and
tumour samples of prostate tissue revealed nuclear dystroglycan
(Figure 2F,G). Detection of unphosphorylated dystroglycan using
the MANDAG2 antibody revealed the majority of full length
43 kDa b-dystroglycan in the cytoplasmic fraction, with some
31 kDa (transmembrane and cytoplasmic domain) and 26 kDa
(cytoplasmic domain). The 43 kDa and 26 kDa species were also
detected to a limited extent in the nuclear fraction. Using an
antibody specific for b-dystroglycan phosphorylated on Y890,
bands of 43 kDa, 31 kDa and 26 kDa were detected in both
cytoplasmic and nuclear fractions and in both normal and tumour
samples. The specific finding therefore from the biochemical analysis
is that the Y890 phosphorylated 31 kDa fragment of dystroglycan,
comprising transmembrane and cytoplasmic domain of dystrogly-
can, is more frequently translocated to the nucleus.
We have demonstrated previously the cell density-dependent frag-
mentation profile of dystroglycan in prostate cancer cell lines includ-
ing LNCaP, PC3 and DU14513. We therefore investigated the
distribution of both phosphorylated and un-phosphorylated cyto-
plasmic and nuclear dystroglycan in normal and tumour cell lines
from prostate. Non-phosphorylated b-dystroglycan was detected in
all four cell lines tested, with the majority of the full-length protein
being detected in the cytoplasmic fraction and a small amount in the
nucleus, whereas the 26 kDa fragment remained cytoplasmic,
and the non-phosphorylated 31 kDa fragment was not detected
(Figure 3B). Analysis of the same samples for Y890 phosphorylated
dystroglycan revealed the presence of full-length and 26 kDa dystro-
glycan in the cytoplasmic and nuclear fractions in all cell lines tested.
Figure 1 | Prostate histopathology. b2dystroglycan
immunohistochemistry in normal prostate (A–D), prostate cancer in situ
showing varying degrees of dystroglycan loss (E–H) and in a bone
metastasis sample (I), (J) where dystroglycan is re-expressed. Scale bars in
all images represent 100 mm.
www.nature.com/scientificreports
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The 31 kDa fragment was only detected in LNCaP cells however,
where it was present exclusively in the nuclear fraction (Figure 3B).
Nuclear targeting of dystroglycan. Several adhesion molecules
undergo membrane proximal cleavage followed by translocation to
the nucleus where the cytoplasmic regions exert an effect on tran-
scription: notable examples being CD44 and notch20,21. Furthermore
a previous report demonstrated androgen-dependent expression of
dystroglycan and stated they had identified androgen response
elements in the dystroglycan gene22. We therefore investigated
whether androgens had any influence on the nuclear targeting of
dystroglycan. We investigated LNCaP cells which have the advan-
tage of exhibiting nuclear translocation of the 31 kDa fragment of
dystroglycan (Figure 3) which recapitulates the findings from
nuclear fractionation of prostate tissue (Figure 2B) and are an
established androgen-responsive cell line. Dihydrotestosterone
(DHT) treatment of LNCaP cells caused a robust relocation of the
androgen receptor to the nucleus, as determined by both immu-
nofluorescence microscopy and by biochemical fractionation
(Figure 4ABD). Using tubulin as a cytoplasmic fraction marker,
and nucleolin as a nuclear fraction marker, almost all androgen
receptor (AR) was found in the nucleus following DHT treatment,
with a corresponding reduction in cytoplasmic AR (Figure 4D).
Unexpectedly there was a clear reproducible and significant (p 5
0.019) relocation of the endogenous b-dystroglycan to the nucleus
followingDHT treatment (Figure 4ACE). Dystroglycan andARwere
therefore targeted robustly and rapidly to the nucleus in response to
DHT stimulation and appeared to co-localise in similar nuclear
compartments. However, despite exhaustive efforts to immunopre-
cipitate dystroglycan andARwith endogenous or tagged proteins, we
were unable to demonstrate any direct or indirect association
between dystroglycan and the androgen receptor by these methods
(Data not shown). Therefore it appears that endogenous dystro-
glycan can be translocated to the nucleus in an androgen-
dependent manner in LNCaP cells, but not in direct association
with the AR.
Transcriptional response to nuclear targeted dystroglycan. As
outlined above, CD44 and notch translocate to the nucleus in a
similar manner to dystroglycan, where, in the case of CD44 and
notch, they regulate transcription. With the evidence that the
dystroglycan gene may contain androgen response elements22 and
can be cleaved at the membrane8,13 and translocated to the nucleus in
an androgen dependent manner (see above) we examined what the
transcriptional response to dystroglycanwas in LNCaP cells. In order
to test more rigorously a role for dystroglycan in the nucleus we used
a construct comprising an n-terminal myristoyl-tag, dystroglycan
cytoplasmic domain and c-terminal GFP tag (Myr-cbDG-GFP23).
We hypothesised that such a construct should effectively mimic
the properties of 31 kDa fragment of dystroglycan in that it is
membrane associated, contains the complete cytoplasmic domain
sequence including NLS24 and it has a GFP tag to allow efficient
visualisation and cell sorting (Figure 5ABC). Furthermore this con-
struct was efficiently translocated to the nucleus without additional
stimulation with androgens thus allowing any transcriptional
response to dystroglycan alone to be detected without the high
background of an androgen-mediated transcriptional response. In
order to compare the effects of nuclear targeting on transcription, we
Figure 2 | Tyrosine phosphorylated b-dystroglycan is in the nucleus of
prostate epithelium in vivo. Immunohistochemistry of paraffin
embeddedTMAof prostate stained for pY890b-dystroglycan shows a clear
presence of tyrosine phosphorylated b-dystroglycan in the nucleus of
prostate epithelium ((A–E) and arrows in magnified regions), scale bar is
100 um and in inset is 50 um. Cellular fractionation of prostate tissue also
revealed the presence of both non-phosphorylated b-dystroglycan (F) or
tyrosine phosphorylated b-dystroglycan (G) in nuclear fractions from
either benign or tumour tissue. For non-phosphorylated b-dystroglycan
the full length 43 kDa and cytoplasmic 26 kDa were the predominant
species found in the nuclear fraction, whereas for phosphorylated b-
dystroglycan the 31 kDa transmembrane and cytoplasmic fragment was
more prominent in the nucleus. Fibrillarin and tubulin are shown as a
nuclear (N) and cytoplasmic (C) fraction markers respectively. Both
tumour samples were from hormone refractory primary TURPs.
www.nature.com/scientificreports
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designed a construct (Myr-cbDGDNLS-GFP) mutated in the
NLS14,24 to prevent translocation to the nucleus. Immunofluo-
rescence analysis of LNCaP cells transiently transfected with these
constructs and enriched by FACS (Supplementary Figure 1) demon-
strated that whilst Myr-cbDG-GFP had both plasma membrane and
nuclear localisation, Myr-cbDGDNLS-GFP had only membrane
(and Golgi) localisation, with no nuclear localisation (Figure 5D).
The findings from the immunofluorescence analysis were corro-
borated by biochemical fractionation which revealed Myr-cbDG-
GFP in both cytoplasmic and nuclear fraction of LNCaP cells,
whereas Myr-cbDGDNLS-GFP was restricted to the cytoplasmic
fraction only (Figure 5EF).
RNA from four independent FACS sorts of LNCaP cells stably
expressing either Myr-cbDG-GFP or Myr-cbDGDNLS-GFP (Sup-
plementary Figure 1) was subjected to microarray analysis using the
Agilent 44 K genome array. The analysis revealed a total of 13 genes
upregulated by a factor of more than 2 and 21 genes downregulated
by a factor of more than 2 (Figure 6). With such a small number of
genes differentially expressed, pathways analysis and Ontology char-
acterisation, performed with PANTHER25 with Cluster 3.0 and
Treeview is not particularly informative (data not shown). In order
to validate the genes that were selected by the microarray data ana-
lysis, all significant hits were subjected also to qPCR analysis from a
separately stored aliquot of the original RNA samples. As can be seen
from Figure 6C, qPCR analysis confirmed 3 genes in particular to be
significantly altered by dystroglycan nuclear targeting; RGS20, ETV1
and BAAT. Without further in-depth analysis, it is difficult to pro-
pose a clear or intuitive function for RGS20 (regulator of G protein
signalling 20)26,27 or BAAT (bile acid coenzyme A: amino acid N-
acetyltransferase)28. ETV1 (ETS translocation variant 1) however, is
an androgen responsive transcription factor which has an established
role in regulation of prostate growth and prostate cancer progression29.
Discussion
In the primary prostate tumour there is progressive loss of dystro-
glycan function through a combination of altered glycosylation of
both a- and b-dystroglycan13 and a concomitant loss of b-dystrogly-
can protein through a series of proteolytic events that 1st remove the
extracellular domain and then the ICD13. Loss of dystroglycan pro-
motes tumour growth in soft agar13,22,30,31, however for EMT, migra-
tion and invasion, some dystroglycan function is required and in
vitro assays clearly demonstrate a requirement for dystroglycan func-
tion to be regained13,22,31. Furthermore, re-expression of dystroglycan
to normal levels or restoration of functional glycosylation inhibits
tumour properties13,30,31. In the present study, whilst the numbers of
patient samples of metastases were limited, a significant number do
show re-expression of dystroglycan in the secondary site supporting
the general hypothesis above. In this regard, loss of dystroglycan
during the EMT process and metastatic spread of prostate cancer,
followed by re-expression of dystroglycan during mesenchymal to
epithelial transition (MET) at a secondary site, mirrors findings with
other cell adhesion molecules such as E-cadherin32.
A surprising finding was the androgen-dependent translocation of
dystroglycan to the nucleus, and moreover the presence of phos-
phorylated dystroglycan in the nucleus of prostate epithelia in vivo.
Although the presence of an NLS on b-DG has been well documen-
ted24,33 and the mechanisms underlying its entry into the nucleus are
credible24, there is no comprehensive understanding of a function for
the presence of dystroglycan in the nucleus thus far. It has been
speculated that b-DG together with the DGC may offer stability to
the nuclear membrane16,34. In silico analyses suggest that there are no
predicted DNA binding regions in DG4, hence DG is unlikely to have
a direct role in transcriptional regulation, but it may regulate tran-
scription through association with other factors in the nucleus. The
recent finding that dystroglycan has a direct role in the organisation
of nuclear architecture and interaction with other nuclear proteins
Figure 3 | b-dystroglycan is also found in the nucleus of prostate cell lines.
(A), shows immunofluorescence localisation of phosphorylated b-
dystroglycan to the nucleus of LNCaP, PNT1A and PNT2C2 cells in vitro.
DAPI staining marks the position of the nuclei. Cellular fractionation of
prostate cell lines of different origins: normal epithelium, PNT1A and
PNT2C2; primary tumour, Shmac5 and metastatic tumour, LNCaP, also
revealed the presence of dystroglycan in the nucleus (N) fraction (B). For
non-phosphorylated b-dystroglycan the predominant nuclear species was
43 kDa (upper panel) whereas the 26 kDa fragment remained in the
cytoplasmic (C) fraction. Tyrosine phosphorylated b-dystroglycan (lower
panel) was found more extensively in the nuclear fraction, and depending
on cell line, sizes ranged from 43 kDa, 31 kDa, 26 kDa, and previously
unreported 17 kDa and 50 kDa species. Tubulin and nucleolin are shown
as a cytoplasmic and nuclear markers respectively.
www.nature.com/scientificreports
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such as emerin and lamin B1 provides further evidence of a role for
dystroglycan in scaffolding or modulation of transcriptionally active
regions in the nucleus16. The biochemical fractionation of prostate
tissue revealed the presence in the nucleus of the 26 kDa fragment of
dystroglycan – equivalent to the cbDG construct used here and
elsewhere13,14. Furthermore the histological analysis and the tissue
fractionation also revealed the presence of tyrosine phosphorylated
b-dystroglycan in the nucleus, both the full length 43 kDa form and a
31 kDa fragment equivalent to the transmembrane and cytoplasmic
regions. Thus the differential translocation of the 43, 31 and 26 kDa
forms of dystroglycan to the nucleus, coupled with the role of andro-
gens, provides a potential mechanism for dystroglycan to have a
regulatory role in prostate cancer progression through altering as
yet unidentified nuclear functions.
The Dag1 gene itself was found to contain androgen response
elements22, and in LNCaP cells dystroglycan expression was induced
by DHT and inhibited by the anti-androgen flutamide22. In our own
experiments where dystroglycan was targeted to or prevented from
entering the nucleus, we did not see any change in dystroglycan
transcript levels, but these experiments were not performed under
strict androgen stimulation conditions. However, nuclear transloca-
tion of AR in response to DHT was not affected by the expression of
the nuclear targeted or nuclear excluded dystroglycan constructs
(Supplementary Figure 2). The LNCaP cell line is growth stimulated
by treatment with DHT, so it is possible that the translocation pro-
cess of dystroglycan is part of the proliferative response rather than
being directly associated with mediating androgen action. Indeed,
the failure to show co-immuno-precipitation between AR and dys-
troglycan would tend to suggest that the translocation was a result of
androgen action rather than part of the androgen response mech-
anism. Dystroglycan is able to translocate to the nucleus in the
androgen-independent prostate cell lines PC3 and DU145 (see
Figure 4 | b-dystroglycan translocates to the nucleus in an androgen-dependent manner. (A), Immunofluorescence staining for androgen receptor
(AR) and endogenous b-dystroglycan (b-DG) in LNCaP cells demonstrates the shift from cytoplasmic in the absence of DHT (-DHT; top panels) to
nuclear in the presence of DHT (1DHT; lower panels). Both AR and b-dystroglycan are clearly cytoplasmic in the absence of DHT and nuclear in the
presence, DAPI staining is shown to indicate the location of the nucleus. Fractionation of LNCaP cells into cytoplasmic and nuclear fractions (B),
(C) reveals the expected dihydrotestosterone (1DHT) dependent translocation of the androgen receptor (AR) from the cytoplasmic to nuclear fraction
(B). In keeping with the immunohistochemistry a significant proportion of the b-dystroglycan is also translocated to the nucleus in the presence of DHT
(C). Tubulin and nucleolin are used as markers of the cytoplasmic and nuclear fractions respectively. (D), (E), quantitative analysis of three independent
cellular fractionation experiments confirms the DHT-dependent shift of b-dystroglycan from cytoplasm to nucleus. N5 3 unpaired two tailed t-test with
95% confidence interval.
www.nature.com/scientificreports
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supplementary figure 4 in reference13), demonstrating that dystro-
glycan translocation to the nucleus in prostate cancer cells is not
necessarily part of the androgen responsemechanismdriven through
the androgen receptor. However, under the conditions of our experi-
ments, and using the androgen responsive LNCaP cell line, it is
formally possible that there could be a causative link, however we
have been unable to demonstrate such an association. These differ-
ences clearly warrant further investigation.
Nonetheless, microarray analysis of LNCaP cells expressing nuc-
lear targeted or nuclear excluded dystroglycan constructs revealed a
significant change in the transcription of relatively few genes. Where
transcriptional changes could be validated by qPCR, ETV1 stood out
as a strong candidate for a role in dystroglycan mediated modulation
of prostate cancer progression. ETS factors can function as positive
or negative regulators of transcription; therefore the precise balance
between cancer promotion and inhibition by ETS factors may con-
trol cancer progression by differentially regulating specific target
genes/oncogenes35. Furthermore, the fusion between androgen-regu-
lated TMPRSS2 and ETS transcription factor gene ERG or ETV1 is
the most frequent genetic alteration that occurs in 40–70% of CaP36.
It has been demonstrated that aberrant expression of ETV1 is not
sufficient to initiate neoplastic transformation but instead may
cooperate with other genetic events to promote prostate cancer
progression37.
The LNCaP cell line used in these studies carries both a mutated
androgen receptor, with promiscuous steroid binding activity and a
TMPRSS2-ETV-1 fusion38,39. Both these features could affect andro-
gen responses and the dystroglycan translocation process. Studies to
Figure 5 | Nuclear targeting of a myristoyl-tagged cytoplasmic dystroglycan construct. Schematic diagram of myristoyl (Myr)-tagged constructs in
association with the plasma membrane. (A), Myr-GFP control, (B), Myr-cytoplasmic b-dystroglycan-GFP (Myr-CbDG-GFP) with intact nulear
localisation sequence (NLS), (C), Myr-cytoplasmic b-dystroglycan-GFP (Myr-DNLSCbDG-GFP) with mutated nulear localisation sequence.
(D), Immunofluorescence localisation of the Myr-tagged constructs as detected by the GFP signal. Myr-GFP localises to the plasma membrane,
Myr-CbDG-GFP localises to the membrane and nucleus, whereas Myr-DNLSCbDG-GFP is excluded from the nucleus, and found in cell-cell junction
and a peri-nuclear compartment. Cellular fractionation and probing with GFP antibody (E) confirmed the presence of Myr-CbDG-GFP in the
cytoplasmic (C) and nuclear (N) fractions, whereas the Myr-DNLSCbDG-GFP construct was recovered exclusively in the cytoplasmic fraction. Tubulin
and nucleolin were used as cytoplasmic and nuclear markers respectively. (F) shows a quantification of 3 representative fractionation experiments,
demonstrating the significantly higher levels (5-fold) of nuclear Myr-CbDG-GFP compared to Myr-DNLSCbDG-GFP. N 5 3 unpaired two tailed t-test
with 95% confidence interval.
www.nature.com/scientificreports
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determine the involvement of dystroglycan nuclear translocation in
response to androgen in other cell lines with differing sensitivities to
androgen such as DuCap and PC3 expressing wildtype AR, are
ongoing.
Advanced stages of CaP are associated with the expression of ETS1
and ETS2. The transcriptional activation of the ETS genes is neces-
sary for the upregulation of ECM degrading proteases such asMMP-
1 and MMP-940. The majority of ETS gene fusions are hormone
regulated, thus explaining the pathogenesis underlying exquisitely
hormone sensitive CaP41. The recurrent fusions of the 59 untrans-
lated region of the TMPRSS2 genes to ERG and ETV1 is seen in ma-
jority of CaP samples and in cell lines containing the TMPRSS2/
ETV1 fusion gene, androgen appears to play a role in mediating
ETS overexpression42,43. Gene microarray studies were used to show
that ETV1 is a novel androgen regulated gene29. ETV1 mRNA and
protein are upregulated in response to ligand activated AR in LNCaP
cells, but there is no detectable ETV1 expression in normal prostate
cells. The ETV1 promoter was shown to be induced by androgens
and recruits AR in the context of chromatin; this in response leads to
ETV-1 regulated endogenous MMP gene activation29. Remarkably,
the disruption of ETV1 expression in both androgen dependent and
independent CaP cells significantly compromises the invasive capa-
city of the cells, suggesting a significant role of ETV1 in CaP meta-
stasis29. Interestingly, the up regulation of ETV1 gene on nuclear
translocation of cb-DG could provide a mechanism for the androgen
mediated regulation of nuclear dystroglycan function. One further
aspect of dystroglycan and ETV1 function that has not been
addressed is signalling through the ERK/MAP kinase pathway.
Dystroglycan is known to be a scaffold for the ERK/MAP kinase
pathway44 which can further direct growth factor and Ras mediated
signalling to specific cellular compartments45. There is clear evidence
of a role for oncogenic ETS transcription factors including ETV146 in
Figure 6 | Microarray analysis of LNCaP cells with nuclear targeted or nuclear excluded CbDG. (A), Fold change in gene expression in response to
dystroglycan nuclear targeting. Red bars represents an upregulation in the presence of nuclear CbDG (NLS), compared to nuclear excluded CbDG
(DNLS), and cyan bars are a downregulation inmRNA in the presence of nuclear CbDG for all four replicates. Abbreviated gene names are indicated and
the actual mean fold change in RNA shown as a bar graph in (B). (C) qPCR confirmation of mRNA levels from the original sample set used for the
microarray analysis demonstrated a significant upregulation or downregulation in only 3 genes, RGS20, ETV1 and BAAT, mean 6 SEM n 5 4.
www.nature.com/scientificreports
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the progression of the majority of prostate cancers. Furthermore
oncogenic ETV1 can mimic Ras/MAPK signalling in prostate cancer
leading to increased cell migration47. Therefore the combined effects
of dysregulation of dystroglycan function through proteolysis lead-
ing to altered cell adhesion andmotility, changes in the scaffolding of
MAPK signalling, nuclear translocation of dystroglycan coupled
with increased ETV1 transcription, which also activates MAPK-
dependent signalling that itself leads to an increase in cell migration,
represents a positive feedback mechanism driving prostate cancer
progression that warrants further investigation.
Methods
Histopathology. Triplicate samples from 163 anonymised archival cases of both
normal and neoplastic paraffin wax-embedded tissues were arrayed into tissue
microarrays using a 0.6 mm punch (Beecher Instruments Inc., Sun Prairie, US).
Approval was obtained for this study from the University of Sheffield Medical
Research Ethics Committee (MREC) approval number MREC/01/4/061. Informed
consent was obtained from all donors. Antigen retrieval, primary antibody staining
and detection and counterstaining were performed and analysed as described
previously8. A further 10 samples of matched pairs of primary prostate carcinoma in
situ and bone metastases were processed separately. Slides were examined by SSC, an
experienced histopathologist, but blind to any case details apart from any obvious
morphology and scored for Gleason tumour grade and the level of intercellular and
basal b-dystroglycan staining as compared to normal control tissue. Samples of
frozen human prostate tissue (benign and tumour) obtained by transurethral
resection of the prostate (TURP) were provided by the Prostate Cancer: Mechanisms
of Progression and Treatment collaborative (ProMPT; Sheffield). A separate tissue
microarray containing 60 tumour samples of Gleason Grade 3 or above were stained
for tyrosine phosphorylated b-dystroglycan using antibody 1709 under the same
conditions as described previously8.
Cell fractionation from tissue. Benign and prostate cancer (hormone refractory)
tissue harvested from anonymised TURP specimens and stored in ice cold RPMI-
1640 media was obtained from the tissue procurement facility at the Department of
Urology, Royal Hallamshire Hospital, Sheffield, UK. Shortly after receiving the
samples, the tissue specimens were minced finely into 3–5 mm3 pieces and washed
with RPMI-1640 at 4uC for 10 mins. Cell fractionation was performed using a
subcellular tissue fractionation kit (Thermo Scientific) according to the
manufacturer’s instructions.
Cell culture and generation of stable lines. LNCaP FGC cells48 were maintained as
described previously13. For experiments requiring androgen treatment LNCaP cells
were grown to about 70% confluence and then cultured for 48 hrs in phenol red free
RPMI 1640 supplemented with 1% charcoal stripped FBS. Following androgen
starvation, the cells were treated overnight (16–18 hrs) with 10 nM
Dihydrotestosterone (DHT) in ethanol. An equivalent amount of ethanol vehicle was
also added to controls. N-terminalmyristoylated b-dystroglycan cytoplasmic domain
constructs23, were transfected into LNCaP cells as described previously13 and sub-
jected to FACS utilising the C-terminal GFP tag (Supplementary Figure 1). PNT2-C2
and PNT1A cells, normal immortalised human prostate epithelial cell lines49 were
cultured in RPMI 1640 supplemented with 10% FBS. Shmac5 cells, a cell line derived
from a moderately differentiated primary prostate tumour50 were cultured in kera-
tinocyte serum free media supplemented with 2% FBS, 5 ng/ml epidermal growth
factor and 25 mg/ml bovine pituitary extract.
Nuclear fractionation. Cells were rinsed in cold PBS and chilled on ice and harvested
in the minimum volume of cold buffer I (0.32 M sucrose, 10 mM Tris-HCl pH 8.0,
3 mM calcium chloride, 2 mM magnesium acetate, 0.1 mM EDTA, 0.5% NP-40,
1 mMDTT, 0.5 mMPMSF and complete protease inhibitor mixture). Harvested cell
lysates were homogenized using a cold dounce homogenizer on ice and spun at 600 g
for 10 mins at 4uC, pellet and supernatant were retained. The pellet was resuspended
in buffer I and mixed with an equal volume of buffer II (2 M sucrose, 10 mM Tris-
HCl pH 8.0, 5 mMmagnesium acetate, 0.1 mM EDTA, 1 mM DTT, 0.5 mM PMSF
and complete protease inhibitor mixture). The resulting mixture was then carefully
overlayed onto 1.8 M sucrose and nuclei were recovered by centrifugation at 30,000 g
for 50 mins. The nuclear pellet was resuspended directly in SDS-PAGE sample buffer
and used as the nuclear fraction in immunoblotting experiments. The retained
supernatant was centrifuged at 9300 g for 10 mins at 4uC and the resultant super-
natant was used as the cytoplasmic fraction. Adapted from51.
Immunofluorescence microscopy and western blotting. LNCaP cells were fixed and
stained for microscopy as described previously52. Widefield microscopy was carried
out on a Leica DMIRE2 fitted with a DC350F digital monochrome camera. Multi-
channel fluorescent images were re-combined post acquisition using Adobe
Photoshop. Confocal images were taken on a Leica TCS SP1 laser scanning confocal
microscope. SDS-PAGE and western blotting was carried out as described prev-
iously52 and quantitative analysis was performed using unpaired two tailed t-test with
95% confidence interval. The following antibodies were used for blotting (WB) and/
or immunofluorescence (IF) applications at the indicated dilutions. Actin (Santa
Cruz; WB 151000), androgen receptor (N-20 Santa Cruz, WB 151000, IF 15100), b-
dystroglycan (MANDAG2; WB 15100, IF 1550), b-dystroglycan (43DAG/8D5
Novocastra, WB 15100, IF 1550) tyrosine phosphorylated b-dystroglycan (170919,
WB 151000, IF 1550) nucleolin (MS-3 Santa Cruz, WB 153000) tubulin (Sigma, WB
152500), fibrillarin (Cell Signalling WB 151000). Species specific secondary anti-
bodies conjugated to horseradish-peroxidase (Sigma, 1510000) were used to detect
western blots by ECL, and TRITC or FITC-conjugated (Vector, 15100) for immu-
nofluorescence microscopy. Cell nuclei were counterstained with DAPI.
Microarray and qPCR. LNCaP cells stably expressing Myr-cbDG-GFP and Myr-
cbDGDNLS-GFP were grown to 90% confluency, trypsinised and resuspended in
FACS buffer. Cells were sorted using a Mo-Flo FACS (Dako Cytomation) using the
GFP signal at 488 nm and fluorescence detected using a 531/40 nm bandpass filter. A
total of 4 independent samples of approximately 43 106 cells were sorted for each cell
line (Supplementary Figure 1). 2 3 106 cells were pelleted and immediately processed
using the nuclear and cytoplasmic fractionation protocol as above and 2 3 106 cells
were used for total RNA isolation using the Stratagene Absolutely RNATM kit. RNA
concentration was analysed using a NanoDrop spectrophotometer. Total RNA was
divided into two aliquots; one for microarray analysis and one for q-PCR, and stored
at 280uC until use.
For microarray analysis: mRNA (Supplementary Figure 1) was amplified, labelled
and hybridized on Agilent 44 K human genome array slides (4 3 44 K format;
MoGene MO, USA). Microarray data was analysed using Agilent Feature Extraction
which provides Linear and LOWESS dye normalization. The data was then read by
GeneSpring which summarised duplicate probes and combined the data from the
separate arrays into a single table including the annotation information from the
array design. Finally, Fold Change and Regulation columns are added in Excel for
estimation of gene expression and normalisation. Differentially expressed genes
across the two experimental conditions were identified based on fold change equal or
greater than 2.0 and p-value equal to or less than 0.05, clustered and visualised using
Cluster Analysis53 and Heatmap Builder54.
For qPCR: total RNA isolated from the sorted cell populations was reverse tran-
scribed to cDNA using SuperScriptTM III first strand synthesis system. Relative gene
expression of differentially expressed genes obtained from the microarray analysis
was performed using gene specific primers with SYBR green real-time PCR master
mix in triplicate (Supplementary Table 2). The data were analysed by iCycler iQ
software by normalising to GAPDH and 2DDCt method was used to calculate the
relative gene expression by comparing Myr-cbDG to the reference sample of Myr
cbDGDNLS.
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